-
New BRIUMVI (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis | Morningstar
Source: Buzz FX / 18 Sep 2024 08:46:15 America/New_York
[GlobeNewswire](/news/globe-newswire) New BRIUMVI (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis Infusion related reactions i
Read more...